CJC-1295 + Ipamorelin
A commonly discussed growth hormone secretagogue combination: a GHRH analog (CJC-1295) paired with a selective GHRP (Ipamorelin). They act on different receptors, and in one human study a different pair (the GHRP hexapeptide GHRP-6 at submaximal doses, plus GHRH) released GH synergistically (Bowers 1990), though this exact pair hasn't been tested together in a published trial. Here's what the published research actually shows.
๐งช Buy CJC-1295 at Swiss Chems โTrack your vials and inventory on paper
Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.
How Each Peptide Works
CJC-1295 and Ipamorelin act on completely different receptors โ that's the entire basis of the stack. Together they hit both the GHRH axis and the ghrelin axis. In normal men, one earlier pair (submaximal GHRP-6 plus GHRH) released GH synergistically (Bowers 1990); this specific pair has not been tested together in a published trial.
CJC-1295 โ GHRH Analog
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that instructs the pituitary to produce GH. It binds to GHRH receptors (GHRH-R) on anterior pituitary somatotrophs, triggering cAMP signaling and GH vesicle release โ exactly the same pathway used by endogenous GHRH.
Ipamorelin โ Selective GHRP
Ipamorelin (NNC-26-0161) is a pentapeptide growth hormone secretagogue and ghrelin receptor agonist (GHS-R1a). It binds to a completely different receptor than GHRH analogs, stimulating GH release through a distinct second messenger cascade involving IP3/DAG signaling and calcium mobilization.
Somatostatin Gating
Somatostatin (SRIF) is the hypothalamic "brake" on GH release. GHRH analogs amplify GH production while somatostatin holds the gates closed. One proposed explanation for why the two classes act synergistically is that GHRPs such as ipamorelin also counter this somatostatin tone; none of the sources cited here tests that mechanism.
Feedback Regulation
A 2006 editorial (Walker) argues that because sermorelin works through the pituitary, its secretagogue-driven GH stays subject to somatostatin feedback, making overdose hard, unlike injected HGH. That safeguard is unproven for this stack: the long-acting DAC form kept GH elevated for 6+ days, with a cumulative IGF-1 effect after repeat doses (Teichman 2006).
GH Pulse Amplification
One proposed model: the pituitary has two pools of GH vesicles: a readily releasable pool (RRP) and a reserve pool. GHRH analogs primarily refill the RRP over time, while GHRPs trigger acute release from the RRP. When dosed together, CJC-1295 primes the pituitary and Ipamorelin triggers the release event โ amplifying the pulse height.
Ipamorelin's Selectivity Advantage
In Raun et al.'s 1998 study in conscious swine, GHRP-6 and GHRP-2 raised ACTH and cortisol, while ipamorelin did not raise either beyond the levels seen with GHRH, even at doses more than 200-fold its GH ED50. None of the secretagogues tested changed prolactin, FSH, LH or TSH in swine. In normal men, a high dose of GHRP-6 raised prolactin and cortisol about 2-fold (Bowers 1990).
Affiliate link: HighPeptides earns a commission on orders.
Why They're Stacked: The GHRH + GHRP Synergy
GHRH analogs and GHRPs act at different receptors and through different intracellular pathways. In normal men, submaximal doses of a GHRP (GHRP-6) given with GHRH released GH synergistically (Bowers 1990). No published trial has tested CJC-1295 and ipamorelin together, so the size of any synergy for this pair is unknown.
CJC-1295
GHRH-R agonist
cAMP pathway
Primes somatotrophs
Refills GH reserve
Ipamorelin
GHS-R1a agonist
IP3/Caยฒโบ pathway
SRIF suppression proposed, untested
Triggers acute release
Proposed: Larger GH Pulse
In one human study of a different pair, submaximal doses of GHRP-6 given with GHRH released GH synergistically (Bowers 1990). The rationale here: the GHRH analog primes the pituitary and the GHRP triggers release. Ipamorelin did not raise cortisol beyond GHRH levels in swine (Raun 1998); the pair has not been tested together in a published trial.
Research basis: Bowers et al. (1990, PMID 2108187) found that submaximal doses of a GHRP (GHRP-6) plus GHRH stimulated GH release synergistically in a study of 18 normal men. A 2020 review by Sinha et al. (PMC7108996) covers sermorelin, GHRP-2, GHRP-6, ibutamoren and ipamorelin, but notes that data on their clinical efficacy largely remain lacking. Neither source tested CJC-1295 with ipamorelin.
The reason growth hormone secretion is pulsatile in the first place is that endogenous GHRH and somatostatin alternate in their dominance โ creating peaks and troughs. GHRPs add a third signal by activating the ghrelin receptor (GHS-R1a); that this also suppresses somatostatin is proposed, not shown in the sources cited here. The rationale for bedtime dosing: injecting CJC-1295 (to prime) and Ipamorelin (to trigger) just before sleep is intended to amplify the sleep-onset GH pulse (untested for this pair), which in men is generally the major, or even the only, daily episode of active GH secretion (Van Cauter & Copinschi 2000).
Published Study Data: CJC-1295 DAC (Teichman et al. 2006)
The landmark pharmacokinetic and pharmacodynamic study of CJC-1295 (with Drug Affinity Complex) was conducted by Teichman and colleagues and published in the Journal of Clinical Endocrinology & Metabolism in 2006. It is the human study this page relies on for CJC-1295. PMID: 16352683.
Study design (Teichman 2006): healthy adults (ages 21โ61), two randomized double-blind placebo-controlled ascending-dose trials (28 and 49 days) โ subcutaneous CJC-1295 (with DAC) given as single ascending doses and then as weekly or biweekly doses. Serial GH and IGF-1 measurements demonstrated dose-dependent, sustained GH and IGF-1 elevation after a single injection The estimated half-life of CJC-1295 was 5.8โ8.1 days, and after multiple doses mean IGF-1 stayed above baseline for up to 28 days.
Ipamorelin Selectivity Data (Raun et al. 1998)
Raun et al. published the foundational characterization of ipamorelin in 1998, describing it as the first GHRP-receptor agonist with a selectivity for GH release similar to that of GHRH. PMID: 9849822.
Cross-species caveat: The hormone-selectivity data above come from conscious swine (Raun 1998); the rat experiments in the same paper measured GH potency only. Head-to-head human comparisons of ipamorelin vs. GHRP-6 vs. GHRP-2 at equivalent GH-producing doses are limited, and none of the sources cited on this page measured cortisol after ipamorelin in humans. Ipamorelin's selectivity in people is inferred from this animal data.
CJC-1295 With DAC vs Without DAC (Mod GRF 1-29)
CJC-1295 comes in two fundamentally different versions with different half-lives, dosing frequencies, and pharmacodynamic profiles. The clinical Teichman 2006 study used CJC-1295 WITH DAC (the long-acting version). In practice, the two are used very differently.
CJC-1295 WITH DAC
Long-Acting / WeeklyCJC-1295 WITHOUT DAC (Mod GRF 1-29)
Short-ActingNaming confusion: "CJC-1295" is often used generically by vendors to refer to Modified GRF 1-29 (without DAC), even though the Teichman 2006 study used CJC-1295 WITH DAC. When ordering or researching, always confirm which version is being discussed. The no-DAC version (Mod GRF 1-29) is the one usually paired with Ipamorelin in pre-bed protocols, on the reasoning that a short half-life gives a discrete pulse rather than sustained GH elevation.
Research Dosing Protocols
The following dosing information reflects practitioner conventions commonly described for this stack; no published trial has tested these doses of the combination. This is not medical advice. All peptide use should be supervised by a qualified healthcare provider.
Pre-Bed Stack (Commonly Described)
- CJC-1295 no DAC (Mod GRF 1-29): no dose established in the sources cited here
- Ipamorelin: no human dose established in the sources cited here
- Route: Subcutaneous injection
- Timing: before sleep; no source cited here sets how long before
- Frequency: varies between practitioners; no source cited here sets one
- Rationale: Intended to coincide with the sleep-onset GH pulse
CJC-1295 DAC Weekly Protocol
- CJC-1295 WITH DAC: no fixed-mg dose established in the sources cited here (Teichman 2006 gave weekly or biweekly doses in its multi-dose trial)
- Ipamorelin: no human dose established in the sources cited here
- Route: Subcutaneous
- Rationale: DAC's long half-life provides baseline GH elevation; Ipamorelin is intended to add acute pulse amplification on top of that baseline (untested for this pair)
- Note: Practitioner convention. Teichman 2006 dosed by body weight (best tolerated at 30 or 60 mcg/kg), not in fixed mg doses
Cycle Approach
- Cycle length: varies between practitioners; no source cited here sets one
- Off period: varies between practitioners; no source cited here sets one
- Rationale: Prevent potential downregulation of GHRH-R with chronic continuous stimulation
- Note: This is practitioner convention โ no human RCT data on optimal cycling intervals for this stack exists
Reconstitution & Injection
- Reconstitute each peptide with bacteriostatic water
- Users commonly draw both into the same syringe for a single injection; no source cited here tested mixing compatibility
- Inject subcutaneously into abdomen or thigh
- Rotate injection sites
- Refrigerate after reconstitution; no source cited here tested how long the reconstituted peptides stay stable
- See Reconstitution Guide
Important: CJC-1295 and Ipamorelin are not FDA-approved for anti-aging, body composition, or performance use. We have not verified their legal or compounding status in any jurisdiction; check local law and ask a licensed provider. Dosing guidance here is derived from practitioner conventions, not from published trials of this stack or FDA-approved labeling. Consult a healthcare provider before use.
CJC-1295 / Ipamorelin vs Other GH Therapies
How the CJC/Ipa stack compares to other common approaches to growth hormone optimization. Note that direct head-to-head human trials are limited โ comparisons rely on independent study data and pharmacological reasoning.
| Parameter | CJC-1295 / Ipamorelin | Sermorelin | MK-677 | Exogenous HGH |
|---|---|---|---|---|
| Mechanism | GHRH-R + GHS-R1a (dual) | GHRH-R only | GHS-R1a (oral) | Direct GH replacement |
| GH pattern | Depends on form: DAC = sustained elevation (Teichman 2006); no-DAC = short pulses | Episodic rather than constant, per an editorial (Walker 2006; opinion, not trial data) | Not covered by the sources cited here | No trial data in the sources cited here |
| Pituitary required? | Yes | Yes | Yes | No โ bypasses pituitary |
| Feedback-regulated? | Not tested in the sources cited here | Argued yes in an editorial (Walker 2006; opinion, not trial data) | Not covered by the sources cited here | Argued no in the same editorial (Walker 2006; opinion) |
| Cortisol elevation | Not raised by ipamorelin beyond GHRH levels in swine (Raun 1998) | Not measured in the sources here | Not significantly raised vs placebo at day 7 (Murphy 1998) | Not measured in the sources here |
| Water retention | Reported by users (not measured in a cited trial) | Not measured in the sources cited here | Reported by users (not a finding of Murphy 1998) | Not covered by the sources cited here |
| Dosing frequency | DAC: weekly or biweekly (Teichman 2006); Mod GRF: not established in the sources cited here | Not established in the sources cited here | Once daily oral | Injected; schedule not reviewed on this page |
| IGF-1 elevation | DAC form: 1.5- to 3-fold for 9โ11 days after one dose (Teichman 2006); no cited data for the stack | Not measured in the sources here | ~40% above placebo (mean of the last 5 of 7 treatment days) in calorie-restricted volunteers (Murphy 1998) | Not covered by the sources cited here |
| Human RCT data? | CJC-1295 DAC: yes (Teichman 2006); Mod GRF 1-29: none in the sources cited here | Not for sermorelin itself in the sources here; a related analog, [Nle27]GHRH-(1-29)-NH2, was tested single-blind with a 4-week placebo lead-in then active drug in all subjects (Khorram 1997, PMID 9141536) | Yes (Murphy 1998) | Not reviewed on this page (see the HGH guide) |
| FDA status | Not approved | Not verified on this page | Not approved (research) | Not reviewed on this page (see the HGH guide) |
Dosing Protocol Details
The following protocol structures reflect practitioner conventions for the CJC-1295 + Ipamorelin stack, not published trial protocols. Protocol selection depends on which form of CJC-1295 is used. All peptide use should be supervised by a qualified healthcare provider.
Protocol A: CJC-1295 With DAC (Long-Acting)
| Peptide | Dose | Frequency | Timing |
|---|---|---|---|
| CJC-1295 (with DAC) | No fixed-mg dose established in the sources cited here (Teichman 2006 dosed by body weight) | Teichman 2006 (DAC alone) gave weekly or biweekly doses; not established for the stack | Evening, fasted (practitioner convention) |
| Ipamorelin | No human dose established in the sources cited here | Not established in the sources cited here | Before bed and/or fasted morning |
Protocol B: CJC-1295 Without DAC / Mod GRF 1-29 (Short-Acting)
| Peptide | Dose | Frequency | Timing |
|---|---|---|---|
| CJC-1295 (no DAC / Mod GRF 1-29) | No dose established in the sources cited here | Not established in the sources cited here | Before bed and/or fasted morning |
| Ipamorelin | No human dose established in the sources cited here | Not established in the sources cited here | Matched to CJC timing (same injection) |
Timing science: In men, the sleep-onset GH pulse is generally the major daily episode of GH secretion, and it tracks slow-wave sleep (Van Cauter & Copinschi 2000). Bedtime dosing is intended to coincide with this pulse; no source cited here sets how long before sleep to inject. Practitioners advise dosing fasted, reasoning that carbohydrates and insulin blunt the GH response; none of the sources cited here tested meal timing or sets a fasting window. Some protocols add a fasted morning dose for a second daytime pulse.
Cycling Protocol
Practitioners run the stack in on/off cycles; no source cited here sets the length of either. Some practitioners also skip days within the active cycle to limit receptor accommodation. The break is intended to let GHRH receptor sensitivity reset; no human study has tested cycle lengths for this stack.
IGF-1 Monitoring
A common practitioner convention is to test IGF-1 at baseline, about 4 weeks into the cycle, and at cycle end, and to reduce dose or pause if it climbs above the age- and sex-adjusted reference range on the lab report. No source cited here sets a monitoring schedule or a target IGF-1 range. Discuss lab monitoring with a qualified healthcare provider.
Estimated Monthly Cost
The cost of the CJC-1295 + Ipamorelin stack varies widely by dose, form, and source; we have not independently verified current pricing. Research chemical vendors may charge less but with variable quality standards.
Effects Timeline (2006 Study Context + Clinical Practice)
From the Teichman 2006 data, a single CJC-1295 DAC injection elevated GH by 2โ10ร for at least 6 days and raised IGF-1 by 1.5โ3ร for 9โ11 days. After multiple doses, mean IGF-1 stayed above baseline for up to 28 days, with evidence of a cumulative effect. The week-by-week notes below are practitioner and user reports, not trial data.
Weeks 1โ2: Sleep & Acute Response
Users often report sleep changes first โ deeper sleep, more vivid dreaming (anecdotal). Some users report mild flushing or warmth immediately post-injection (anecdotal). No visible body composition changes expected this early.
Weeks 3โ4: Recovery & Skin
Some users report better recovery between training sessions and skin texture changes. For the daily no-DAC stack, no published study reports when (or whether) IGF-1 rises above baseline; a blood test is the only way to check. Some users report improved joint comfort.
Weeks 6โ8: Body Composition
Some users report body composition shifts by this point, alongside consistent training and adequate protein. No published trial of this stack has measured body composition, so whether these changes occur, and how large they are, is unknown.
GH Secretagogue Cycling Patterns
Cycling GH secretagogues is a common practitioner convention, for two stated reasons: to limit possible receptor downregulation from chronic GHRH stimulation, and to build in safety margins given limited long-term human data. Cycle lengths vary between practitioners and none has been tested in a trial; three patterns are commonly described.
Short Cycle
A run of weeks on, followed by a shorter break. One commonly described pattern for CJC-1295 / Ipamorelin; longer conventions (months on) are also used. No source cited here sets either length. The off period is intended to let receptor sensitivity recover, though this has not been measured in humans.
Pulse Cycle (Conservative)
Short, equal on and off blocks, repeated (no source cited here sets their length). Used when faster desensitization is a concern or for peptides with higher receptor downregulation potential. Less total exposure but more frequent interruptions. Some practitioners prefer this pattern for extended, long-running research protocols.
Continuous Use
Some practitioners reserve uninterrupted long-term use for approved therapies (e.g., semaglutide, tirzepatide, approved HGH formulations); that is convention, not a rule from the sources cited here. None of the sources cited here has long-term continuous-use human data for CJC-1295/Ipamorelin.
Don't stop abruptly: Some practitioners taper at the end of a GH secretagogue cycle rather than stopping cold, reasoning that the GH axis may adapt to chronic stimulation and need time to recalibrate. This has not been studied, and no source cited here sets a taper length or schedule.
What to Expect: Week-by-Week Timeline
Timeline of effects reported by users and practitioners. Apart from the GH and IGF-1 data in Teichman 2006 (CJC-1295 DAC alone, no ipamorelin), none of it comes from a published trial, and no trial has tested this stack. Individual responses vary based on baseline GH/IGF-1, age, diet, sleep quality, and dosing protocol.
๐ฌ Community reports (anecdotal): The most consistent first-hand report on this stack is sleep โ long-term users who once woke up four or five times a night describe sleeping straight through after a few weeks. These are self-reported forum experiences, not a controlled sleep study, and the one cited trial of nightly GHRH-analog dosing found self-reported sleep quality unaffected after 16 weeks (Khorram 1997, PMID 9141536), so treat the "sleep through the night" effect as unproven.
๐ง The water-weight nobody warns about: A practical caution most write-ups omit: users of this stack report fluid retention (not measured in a cited trial), occasionally waking up several pounds heavier overnight with no change in body fat. Users describe it as transient water rather than fat gain, and it surprises people who weigh in daily. This is anecdotal community observation, not trial data; flag any persistent or rapid swelling to a clinician.
Side Effects & Safety Considerations
Based on Teichman 2006 (human CJC-1295 DAC trials) and Raun 1998 (ipamorelin, animal data), plus broader GH secretagogue literature. The side-effect list below is mostly user-reported (flushing is the exception, noted below); neither cited study reports these effects or their frequency. In Teichman 2006, CJC-1295 DAC was safe and relatively well tolerated, particularly at 30 or 60 mcg/kg. None of the sources cited here tested ipamorelin's tolerability in humans.
IGF-1 Monitoring
Chronically elevated IGF-1 is a theoretical cancer concern; none of the sources cited here addresses it. Practitioners commonly test IGF-1 on the schedule above and aim to keep it from going supraphysiological; no source cited here sets that schedule or a target range. Avoid use if IGF-1 is already elevated.
Active Cancer Contraindication
Practitioners treat active malignancy, or a history of malignancy responsive to GH/IGF-1, as a contraindication to GH/IGF-1 axis stimulation; none of the sources cited here addresses this. Discuss any cancer history with a qualified healthcare provider.
Water Retention Management
Users report mild water retention; no source cited on this page measured it for this stack or tested whether it is dose-dependent. If significant edema occurs, pause use and talk to a clinician.
Receptor Downregulation Risk
Chronic continuous GHRH receptor stimulation โ particularly with CJC-1295 DAC โ may cause receptor downregulation over time. This is the theoretical basis for cycling protocols (time off between use periods). Short-acting Mod GRF 1-29, given as discrete pulses, is thought to carry less of this risk; how fully it clears between doses is not quantified in the sources cited here.
Published Sources
All clinical data cited on this page is sourced from peer-reviewed publications. PubMed IDs and DOIs are provided for independent verification.
Key Takeaways
What We Know
- CJC-1295 (with DAC) produced sustained GH elevation for 6+ days after a single dose in a randomized, placebo-controlled human trial (Teichman 2006, PMID 16352683)
- In swine, ipamorelin released GH without raising ACTH or cortisol beyond the levels seen with GHRH, even at more than 200-fold its GH ED50, unlike GHRP-6 and GHRP-2 (Raun 1998, PMID 9849822)
- GHRH analogs and GHRPs act on different receptors (GHRH-R vs GHS-R1a); submaximal GHRP-6 plus GHRH released GH synergistically in normal men (Bowers 1990, PMID 2108187)
- CJC-1295 DAC was safe and relatively well tolerated in healthy adults, particularly at 30 or 60 mcg/kg, with no serious adverse reactions reported (Teichman 2006)
- Ipamorelin's GH selectivity data come from animals (swine); none of the sources cited here measured its cortisol effect in humans (Raun 1998)
- In men, the sleep-onset GH pulse is generally the major daily GH episode (Van Cauter & Copinschi 2000, PMID 10984255), which is the rationale for pre-bed dosing
What We Don't Know (Or Should Be Cautious About)
- No human RCT directly compares the full CJC-1295 + Ipamorelin stack (both peptides together) vs. placebo or monotherapy
- Whether somatostatin feedback makes secretagogues safer than exogenous HGH is untested; the DAC form produced sustained, cumulative GH/IGF-1 elevation (Teichman 2006)
- The Teichman 2006 study used CJC-1295 WITH DAC โ none of the human trials cited here tested Modified GRF 1-29 (no DAC)
- Mod GRF 1-29 (no DAC) is described as short-acting and used for discrete GH pulses, but its half-life and GH duration are not quantified in the sources cited here
- Long-term (multi-year) safety data for this stack in otherwise healthy adults is absent
- GHRH receptor downregulation from chronic CJC-1295 DAC use is a theoretical concern โ not yet characterized in human studies
- No cited trial of this stack measured body composition, so whether it changes is unknown; any effect would be indirect (GH โ IGF-1 โ tissue effects)
- No cited source sets an IGF-1 monitoring schedule or target range; chronically elevated IGF-1 carries theoretical oncological risk
- Vendor quality for research peptides varies widely โ third-party HPLC testing is strongly advisable
- We have not verified regulatory or compounding status in any country โ verify local laws before use
Research Source
Swiss Chems publishes third-party COAs for selected products (vendor-published; verify before relying on them).
Affiliate links support HighPeptides at no extra cost. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).
Recommended Supplies
Essential supplies for peptide preparation and subcutaneous administration of the CJC-1295 / Ipamorelin stack.
Affiliate links support HighPeptides at no extra cost.
Related Research
More HighPeptides research pages related to growth hormone peptides, secretagogues, and protocols.
Disclaimer: This page is for educational and informational purposes only. It is not medical advice. CJC-1295 and Ipamorelin are not FDA-approved for anti-aging, body composition improvement, or performance enhancement. CJC-1295 (with DAC) was tested in randomized, placebo-controlled trials in healthy adults (Teichman 2006) but was not developed into an approved drug. We have not verified their legal or compounding status in any jurisdiction. Always consult with a qualified healthcare provider before starting any peptide protocol.
All clinical data cited on this page is sourced from published peer-reviewed research. PubMed IDs and DOIs are provided for independent verification. Observational and preclinical data is identified as such throughout.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.